Brent Hatzis-Schoch - 30 Jan 2025 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Officer Title: Chief Operating Officer and General Counsel
Signature
/s/ Brent Hatzis-Schoch
Issuer symbol
BDTX
Transactions as of
30 Jan 2025
Net transactions value
$0
Form type
4
Filing time
31 Jan 2025, 16:35:06 UTC
Previous filing
15 Feb 2024
Next filing
23 Jan 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Award $0 +75,000 +893% $0.000000 83,400 30 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDTX Stock Option (Right to Buy) Award $0 +175,000 $0.000000 175,000 30 Jan 2025 Common Stock 175,000 $2.52 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
F2 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Officer Title: Chief Operating Officer and General Counsel